Pellagra (off-label use): Oral: 100 mg every 6 hours for several days (or until resolution of major signs and symptoms), followed by 50 mg every 8 to 12 hours until skin lesions heal (Hegyi 2004), or 500 mg once daily for several weeks (Jen 2010).
There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).
There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).
Pellagra (off-label use): Oral: 10 to 50 mg every 6 hours until resolution of signs and symptoms (Hegyi 2004)
Refer to adult dosing.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Tablet, Oral:
Generic: 100 mg, 500 mg
Tablet, Oral [preservative free]:
Generic: 500 mg [DSC]
Yes
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Injection:
Generic: 100 mg/mL (10 mL, 30 mL)
Oral: Administer with food (preferred).
Dietary supplement: For use as dietary supplement when niacinamide intake may be inadequate.
Pellagra (treatment/prophylaxis)
Niacinamide may be confused with niacin, niCARdipine
The following adverse drug reactions are derived from product labeling unless otherwise specified.
Postmarketing: Hepatic: Abnormal hepatic function tests
Hypersensitivity to niacin, niacinamide, or any component of the formulation
Disease-related concerns:
• Diabetes: Use with caution in patients with diabetes mellitus; may interfere with glucose control.
• Gallbladder disease: Use with caution in patients with active gallbladder disease; can exacerbate.
• Gout: Use with caution in patients predisposed to gout.
• Peptic ulcer: Use with caution in patients with peptic ulcer.
None known.
HMG-CoA Reductase Inhibitors (Statins): Niacinamide may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy
Water-soluble vitamins cross the placenta (IOM 1998).
Used by the body as a source of niacin; is a component of two coenzymes which is necessary for tissue respiration, lipid metabolism, and glycogenolysis; does not have hypolipidemia or vasodilating effects.
Half-life elimination: Dose-dependent: ~1.5 hours following a 1 g dose; ~4 hours following a 2 g dose; ~9 hours following a 6 g dose (Stratford 1992).
Time to peak, serum: ~1 to 3 hours (Stratford 1992).
Excretion: Urine (primarily as metabolites) (Stratford 1992).
Tablets (Niacinamide Oral)
500 mg (per each): $0.03 - $0.04
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.